cally against the growth of mKSA cells (17, 19) . The MSB cell line was established from MMuSV-induced tumor in C57BL/6 mice (20) . The cells were passed in tissue culture by exposure to 0.25% trypsin. They are good target cells for in vitro 51Cr release assay (20) .
Removal of B Cells and Phagocytic Cells. The technique described by Julius et al. (21) was used. About 30% of the starting spleen cell population was recovered in the nonadherent fraction; of these 1-3% (as compared to 40-45% in the unfraetionated population) were surface immunoglobulin-positive cells and 0.3% phagocytic cells (as compared to about 5% in the unfractionated population) as judged by latex particle ingestion.
Removal of T Cells. AKR anti-Thy 1.2 C3H antibody was kindly obtained from H. Holden, National Cancer Institute, Bethesda, Md. The preparation of this serum and the treatment of lymphoid cells were performed according to the technique described in detail (22) . This antiserum lysed more than 97% of C3H thymocytes and 35-40% of C3H spleen cells by trypan blue dye exclusion. The T-cell response of spleen cells to phytohemagglutinin was abolished after treatment, although the B-cell response to lipopolysaccharide was left intact.
~a Cr Release Assay. The assay was performed in the wells of flat bottom microplates. C57SV target cells were trypsinized and 1 × 104 cells and 5 ~Ci Na51CrO4 in 0.2 ml RPMI-1640 medium containing 5% fetal bovine serum were added to each well. After 18 h at 37°C in a CO~ incubator, the target cells were washed and effector cells were added in 0.2 ml voi in various lymphocyte:target cell ratios. After 6 h incubation at 37°C in a CO2 incubator, the plates were centrifuged at 350 g for 5 min. 0.1 ml of the supernate was removed for counting. 
Results
The data of the first experiment (Table I) demonstrate that after i.p. immunization of CBF1 mice with 2 × 107 C57SV cells, cell-mediated cytotoxic response was generated in the spleens with peak activity at day 8, and this activity decreased to low levels by day 14. This finding is in accordance with earlier reports (18, 19) . CBF1 mice treated i.p. with cy 2 d before C57SV cell immunization generated markedly higher levels of cytotoxic response which was still detected at day 20. Cy at a concentration of 100 mg/kg had an optimal augmenting effect, whereas higher concentrations were less effective. These results implied that cy administered in vivo before antigenic immunization can augment the magnitude and kinetics of cell-mediated cytotoxic response against SV40 transformed cells. In Table II the relationship between cy administration before or after antigen immunization and the cytotoxic response generated in vivo is observed. CBFI mice were treated i.p. with 100 mg/kg of cy at various times before or after i.p. immunization with 2 X 107 C57SV cells. The cytotoxicity assay was performed on day 8 after antigen inoculation. The optimal time for cy treatment was 2 d before in vivo antigen immunization. The effect of cy decreased with an increase in time interval between cy administration before antigen inoculation and C57SV cell immunization. Drug application simultaneously with, or 2 or 4 d after antigen immunization had no augmenting effect, whereas, drug administration 6 d after immunization resulted in suppression of cytotoxic response. These results implied that cy administered 2 d before antigen had an optimal augmenting effect on cell-mediated cytotoxic response, whereas cy administration 6 d after antigen had a suppressive effect. In the last experiment CBF1 mice were treated i.p. with 100 mg/kg of cy and 2 d later were injected i.v. with various cell populations from normal CBF1 mice and then inoculated i.p. with 2 X 107 C57SV cells. The cytotoxicity assay was performed 8 d later. The results (Table III) indicate that transfer of T cells abolished the cy-induced augmentation of cytotoxic response, implying that cy-sensitive T cells suppressed the in vivo generation of specific cytotoxic T lymphocytes against SV40 transformed cells.
Discussion
The new aspects of the present study are that pretreatment of mice with cyclophosphamide before immunization with syngeneic tumor-associated antigens results in marked augmentation of their ability to generate in vivo antigen-specific cellmediated cytotoxic response. Because the in vitro cytotoxic reactivities observed in syngeneic tumor systems are often weak or even undetectable, cy treatment may be used to convert such state of low to high responsiveness. Moreover, by such manipulation, it is hoped to achieve more effective ways for immunotherapy of tumors (13, 14) . We are currently studying the possible augmenting effect ofcy on in vivo rejection of lethal syngeneie tumors. The conversion to high responsiveness by cy can be reverted to a state of low responsiveness by reconstituting the cy-treated animals with normal T cells, suggesting that in vivo cy-sensitive T cells suppress the in vivo generation of T cells cytotoxic against SV 40 transformed cells. An interesting observation in the present study is that cy treatment of mice 6 d after antigen immunization resulted in suppression of cell-mediated cytotoxic response. This phenomenon which is in accord with the one reported in an allogeneic system (23) is now under study. Our results of augmentation of cell-mediated immunity against tumorassociated antigens are similar to those demonstrating that cy enhanced delayed type hypersensitivity reactions by elimination of suppressor B cells (7) (8) (9) and recently augmented cell-mediated cytotoxic response against alloantigens by elimination of suppressor T cells (10) . These reports together with the data presented here favor the concept that T-cell-immune responsiveness in vivo against a variety of antigens is under the control of cy-sensitive suppressor T cells. Summary When cyclophosphamide was administered to mice before immunization with syngeneic SV40 transformed cells, the specific immune response elicited, as was measured by in vitro 51Cr release assay was stronger and lasted longer when compared to the response generated in noncyclophosphamide-treated mice. The augmentation effect of the drug was dependent on cyclophosphamide concentration being optimal at 100 mg/kg and on the time of drug administration in relation to antigen immunization being optimal at 2 d before antigen administration. Transfer of T cells from normal syngeneic mice to drug-treated animals abolished the cyclophosphamideinduced augmentation of immune response. These results implied that cyclophosphamide sensitive T cells suppressed the in vivo generation of specific effector T cells against SV40-induced tumor-associated antigens.
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